CardioExchange Archive

December 9th, 2010

Meta-Analysis Finds Aromatase Inhibitors Increase Risk for Heart Disease

Larry Husten, PHD

A new meta-analysis has found that postmenopausal women taking aromatase inhibitors (AIs) instead of tamoxifen to treat breast cancer appear to be at increased risk for cardiovascular complications. The results were presented at the San Antonio Breast Cancer Symposium. Previous studies suggested that women taking AIs were more likely to develop cardiovascular disease, while women taking […]

---

December 6th, 2010

Meta-Analysis: Daily Aspirin Reduces Cancer Deaths

Larry Husten, PHD

A new analysis finds that long-term aspirin use reduces deaths from several common cancers. Previous studies had only shown a convincing benefit in colorectal cancer. In the new meta-analysis, appearing online in the Lancet, Peter Rothwell and colleagues combined data from more than 25,000 patients enrolled in long-term randomized trials of aspirin. They showed that […]

---

November 29th, 2010

Study Finds No Link Between Cancer and Antihypertensives, Except for ARB-ACE Inhibitor Combo

Larry Husten, PHD

A new meta-analysis has found no evidence of a large cancer risk for most common antihypertensive agents, but did find strong evidence, largely based on one trial, for at least a 10% increase in cancer risk with the rarely used angiotensin-converting-enzyme (ACE) inhibitor and angiotensin-receptor blocker (ARB) combination. In a paper in the Lancet Oncology, […]

---

September 17th, 2010

FDA Announces Safety Review of Pioglitazone

Larry Husten, PHD

The FDA announced today that it was undertaking a safety review of pioglitazone (Actos). The review was initiated after the FDA received data from Takeda, the drug’s manufacturer, suggesting a possible increase in bladder cancer in patients taking the drug for more than 2 years. The data are taken from a planned 5-year analysis of […]

---